19:50:12 EDT Tue 13 Oct 2026
Enter Symbol
or Name
USA
CA



Tilray Brands Inc (2)
Symbol TLRY
Shares Issued 96,049,515
Close 2026-10-09 C$ 5.03
Market Cap C$ 483,129,060
Recent Sedar+ Documents

Tilray Brands wins nod for in-house testing in Portugal

2026-10-13 16:04 ET - News Release

Mr. Rajnish Ohri reports

TILRAY MEDICAL STRENGTHENS GLOBAL MEDICAL CANNABIS SUPPLY CHAIN WITH APPROVAL TO BRING CRITICAL EU-GMP QUALITY TESTING IN-HOUSE, ACCELERATING PRODUCT RELEASE ACROSS REGULATED GLOBAL MARKETS

Tilray Medical, a division of Tilray Brands Inc., has hit a key regulatory milestone in Europe: Infarmed, Portugal's National Authority of Medicines and Health Products, has approved the quality control laboratory at Tilray Medical's European Union-good manufacturing practice-certified facility in Cantanhede, Portugal, to conduct microbiological and chemical/physical testing in-house. The approval gives Tilray Medical greater command over critical quality testing, accelerates product release capabilities and strengthens its Portugal facility as a strategic launchpad for pharmaceutical-grade medical cannabis supply across regulated international markets.

With this authorization, Tilray Medical further differentiates its European production platform by embedding advanced testing capabilities directly within its EU-GMP infrastructure. The approval reinforces Cantanhede as a strategic center for cultivation, production, testing and international supply, and comes as demand for trusted, pharmaceutical-grade medical cannabis continues to grow across regulated markets.

Rajnish Ohri, president, international, Tilray Brands, stated: "As regulated medical cannabis markets continue to mature, the companies best positioned to lead will be those that combine pharmaceutical-grade quality, regulatory discipline and reliable global supply at scale. Tilray has built one of the world's leading EU-GMP-certified medical cannabis operations, and this approval further strengthens our platform in Portugal by bringing advanced quality testing closer to cultivation and production. It gives us greater speed, control, and flexibility across our international supply chain while reinforcing the infrastructure and technical expertise required to serve patients, physicians, pharmacies and commercial partners with trusted medical cannabis products in high-standard markets around the world."

For Tilray Medical, bringing critical quality testing in-house creates an important operational advantage in the fast-evolving global medical cannabis market. By reducing reliance on third party testing for flower lots, the company can lower batch-release costs, shorten testing timelines and move product more efficiently from harvest to release and sale. These capabilities strengthen Tilray Medical's ability to manage supply across key international markets, including Germany, the United Kingdom, Poland, Italy and other regulated medical cannabis markets, while supporting more reliable access for patients and commercial partners.

This milestone builds on Tilray Medical's broader international momentum, including increased output at its EU-GMP-certified Portugal facility and the expansion of Tilray Medical-branded cannabis medicines in the United Kingdom through Lyphe Clinic and Lyphe Dispensary. Together, these initiatives strengthen Tilray Medical's position as a trusted global medical cannabis supplier with the infrastructure, regulatory expertise and commercial reach to compete in high-standard pharmaceutical markets.

About Tilray Medical

Tilray Medical is dedicated to transforming lives and fostering dignity for patients in need through safe and reliable access to a global portfolio of medical cannabis brands, including Tilray Medical, Good Supply, Redecan, ARX and Broken Coast. Tilray grew from being one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first GMP-certified cannabis production facilities in Europe, first in Portugal and later in Germany. Today, Tilray Medical is a global leader in medical cannabis, having served patients in more than 20 countries across five continents.

About Tilray Brands Inc.

Tilray Brands is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness and entertainment, elevating lives through moments of connection. Tilray's mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray's unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods and craft beverages.

We seek Safe Harbor.

© 2026 Canjex Publishing Ltd. All rights reserved.